D Lenihan

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. pmc Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors
    Daniel J Lenihan
    Vanderbilt Heart and Vascular Institute, Nashville, Tennessee 37232 8802, USA
    Oncologist 18:900-8. 2013
  2. doi request reprint Cardiac toxicity in cancer survivors
    Daniel J Lenihan
    Divison of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee, USA
    Cancer 119:2131-42. 2013
  3. doi request reprint Late cardiac effects of cancer treatment
    Daniel J Lenihan
    Division of Cardiovascular Medicine, Vanderbilt Heart and Vascular Institute, Nashville, TN 37232 8802, USA
    J Clin Oncol 30:3657-64. 2012
  4. pmc Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
    D Lenihan
    Department of Cardiovascular Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Ann Oncol 23:791-800. 2012

Collaborators

Detail Information

Publications4

  1. pmc Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors
    Daniel J Lenihan
    Vanderbilt Heart and Vascular Institute, Nashville, Tennessee 37232 8802, USA
    Oncologist 18:900-8. 2013
    ..However, cardiovascular (CV) events, including hypertension, heart failure, left ventricular systolic dysfunction, and QT prolongation, have emerged as potential adverse events (AEs) with TKI therapy...
  2. doi request reprint Cardiac toxicity in cancer survivors
    Daniel J Lenihan
    Divison of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee, USA
    Cancer 119:2131-42. 2013
    ..Recognition of specific cancer therapy and the increased cardiovascular risk is an ongoing task that will remain of paramount importance for optimal outcomes among cancer survivors...
  3. doi request reprint Late cardiac effects of cancer treatment
    Daniel J Lenihan
    Division of Cardiovascular Medicine, Vanderbilt Heart and Vascular Institute, Nashville, TN 37232 8802, USA
    J Clin Oncol 30:3657-64. 2012
    ..Future research on late cardiac effects in cancer survivors needs to include advanced cardiac imaging techniques, novel cardiac biomarkers, and genetic determinants of response to cancer treatment...
  4. pmc Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
    D Lenihan
    Department of Cardiovascular Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Ann Oncol 23:791-800. 2012
    ..As HER signaling pathways are not only involved in oncogenesis, but also in myocardial homeostasis, an analysis of cardiac safety data was undertaken in a large group of patients treated with pertuzumab...